Alts Watch Healthcare Beat: $1.1bn supporting novel therapies, T-cell research

New treatments for cancer, rheumatoid arthritis and diabetes are on the horizon thanks to a series private capital deals over the past week.

Alternative investment firms leading the way were: H.I.G. Capital; BlackRock; Surveyor Capital (a Citadel company); New Enterprise Associates; Deerfield Management and Bain Capital Life Sciences.

Below is our weekly run-down of all healthcare-oriented deals $40 million and up for the week ending January 31.

BridgeBio Pharma

• The deal: $400 million in convertible senior notes.
• The players: Aiming to attract . . .
  

  Continue Reading

  Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.

  Monthly

  $30

  A pay-as-you-go plan to get you started

  → Instantly unlock all new and archived articles

  → Daily, weekly and monthly e-mail newsletters

  → Access to the weekly AW Deal Watch by AW Research

  Join Now

  Annual

  $300

  Required for access to AW Research

  Get more for less - 20% discount over monthly

  → Everything in Monthly PLUS:

  → Access to articles and data from AW Research

  → AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators

  Join Now
  Read more about: Alts Watch Healthcare BeatDeerfield ManagementKhosla VenturesLife SciencesNew Enterprise AssociatesSofinnovaT. Rowe PriceWellington Management